Gazyvaro in CLL
Follicular lymphoma (FL)
Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL.1
Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.1
You can find information about Gazyvaro in 1L FL here.
You can find information about Gazyvaro in R/R FL here.
Chronic lymphocytic leukaemia (CLL)
Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine-based therapy.1
1L, first-line; AE, adverse event; CLL, chronic lymphocytic leukaemia; FL, follicular lymphoma; IRR, infusion-related reaction; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory.
- Gazyvaro Summary of Product Characteristics.
Date of preparation: November 2019